GC Biopharma USA, Inc., a leader in plasma-derived products, announced today the presentation of new data at the 2026 ...
GC Biopharma USA, Inc., a leader in plasma-derived products, announced today that it will host a lunch symposium and support ...
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Bank of America Global Healthcare Conference 2026 May 13, 2026 2:20 PM EDTCompany ParticipantsDouglas Love - CEO, President ...
Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patientsOSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE ...
The global Kawasaki disease market is set for steady growth, propelled by rising disease incidence, better clinical recognition, and advancements in pediatric care. Kawasaki disease, an acute ...
It is the first targeted treatment for gMG to be cleared for NHS use in England, after two others – Argenx's Vyvgart (efgartigimod) and UCB's Zilbrysq (zilucoplan) – were deemed not to be ...
Q 2026 Total Revenue of $114.5 Million, Flat Year-Over-Year 1Q 2026 ASCENIV Revenue +28% Year-Over-Year; BIVIGAM Revenue -54% Year-Over-Year1Q ...
Q1 2026 Earnings Call May 6, 2026 4:30 PM EDTCompany ParticipantsAdam Grossman - Co-Founder, President, CEO & DirectorP.
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company ...
24d
Argenx Showcases Broad VYVGART and Pipeline Gains at AAN 2026 to Bolster Neuromuscular Leadership
According to Spark, TipRanks’ AI Analyst, ARGX is a Outperform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results